CN106139019A - A kind of Chinese medicine composition improving dementia and its preparation method and application - Google Patents
A kind of Chinese medicine composition improving dementia and its preparation method and application Download PDFInfo
- Publication number
- CN106139019A CN106139019A CN201610649985.XA CN201610649985A CN106139019A CN 106139019 A CN106139019 A CN 106139019A CN 201610649985 A CN201610649985 A CN 201610649985A CN 106139019 A CN106139019 A CN 106139019A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- chinese medicine
- medicine composition
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 206010012289 Dementia Diseases 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 152
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 31
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 29
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 29
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 29
- 235000013976 turmeric Nutrition 0.000 claims abstract description 29
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 28
- 241000572565 Alpinia oxyphylla Species 0.000 claims abstract description 28
- 208000000655 Distemper Diseases 0.000 claims abstract description 28
- 244000294611 Punica granatum Species 0.000 claims abstract description 28
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 28
- 229940106134 krill oil Drugs 0.000 claims abstract description 28
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 28
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 28
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 28
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 27
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 27
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 27
- 229940094952 green tea extract Drugs 0.000 claims abstract description 27
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 27
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 27
- 241000605447 Anemarrhena Species 0.000 claims abstract description 26
- 229930191283 anemarrhena Natural products 0.000 claims abstract description 26
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 26
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 24
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 24
- 241000146384 Glaux Species 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000012141 concentrate Substances 0.000 claims description 27
- 238000010992 reflux Methods 0.000 claims description 27
- 239000007788 liquid Substances 0.000 claims description 26
- 239000000706 filtrate Substances 0.000 claims description 24
- 238000001035 drying Methods 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 19
- 239000012467 final product Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 241000208966 Polygala Species 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 230000003292 diminished effect Effects 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000005507 spraying Methods 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 235000011201 Ginkgo Nutrition 0.000 claims description 4
- 241000218628 Ginkgo Species 0.000 claims description 4
- 241001165494 Rhodiola Species 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 4
- 241000219095 Vitis Species 0.000 claims description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 4
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 4
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 235000009569 green tea Nutrition 0.000 claims description 4
- 241000239366 Euphausiacea Species 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000010779 crude oil Substances 0.000 claims description 3
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- -1 filters Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 230000036571 hydration Effects 0.000 claims description 3
- 238000006703 hydration reaction Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000008513 turmeric extract Substances 0.000 claims description 2
- 229940052016 turmeric extract Drugs 0.000 claims description 2
- 235000020240 turmeric extract Nutrition 0.000 claims description 2
- 239000004575 stone Substances 0.000 claims 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000002893 slag Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 12
- 210000002569 neuron Anatomy 0.000 abstract description 8
- 238000002347 injection Methods 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 230000001976 improved effect Effects 0.000 abstract description 4
- 238000010171 animal model Methods 0.000 abstract description 3
- 238000012827 research and development Methods 0.000 abstract description 3
- 206010029350 Neurotoxicity Diseases 0.000 abstract description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 230000010534 mechanism of action Effects 0.000 abstract description 2
- 230000007135 neurotoxicity Effects 0.000 abstract description 2
- 231100000228 neurotoxicity Toxicity 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 description 20
- 241000700159 Rattus Species 0.000 description 17
- 235000008504 concentrate Nutrition 0.000 description 16
- 230000008021 deposition Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 235000014666 liquid concentrate Nutrition 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- RHAXKFFKGZJUOE-UHFFFAOYSA-N 7-acetyl-6-ethyl-3,5,8-trihydroxy-9,10-dioxoanthracene-1,2-dicarboxylic acid Chemical compound O=C1C2=CC(O)=C(C(O)=O)C(C(O)=O)=C2C(=O)C2=C1C(O)=C(CC)C(C(C)=O)=C2O RHAXKFFKGZJUOE-UHFFFAOYSA-N 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000004335 litholrubine BK Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of Chinese medicine composition improving dementia and its preparation method and application.A kind of Chinese medicine composition improving dementia of the present invention, including following components: anemarrhena asphodefoides extract, ginkgo biloba p.e, Turmeric P.E, soybean lecithin, gadol extract, milkwort extract, Fructus Alpinae Oxyphyllae extract, green-tea extract, grape seed extract, phosphatidyl serine, Y aminobutyric acid, krill oil-bound distemper and Punica granatum L. polyphenol.The Chinese medicine composition of the present invention can obviously reduce β AP plaque area in brain, and can be obviously improved around injection zone and the form of regional nerve cell and quantity farther out, and the neurotoxicity causing β AP has protective effect.Meanwhile, this experiment is by studying effect and the mechanism of action of this Chinese medicine composition dementia animal model, and the Chinese medicine for research and development treatment dementia further provides objective basis.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, particularly to a kind of Chinese medicine composition improving dementia and preparation side thereof
Method and application, the invention belongs to technical field of traditional Chinese medicines.
Background technology
Disease in terms of the aging of social development and population, the mental hygiene of people becomes increasingly conspicuous, and especially endangers
Evil dementia the most serious, the morbidity of dementia increases with the growth at age, is to occur at the one of Senectitude and presenium
Plant primary brain atrophy, i.e. in the state of there is no the disturbance of consciousness, memory, thinking, analysis judgement, visual space identification, mood etc.
The obstacle of aspect.Patient lives dependent life.This disease severely impacts the quality of life of patient, gives country, society and family
White elephant is brought in front yard.From now on the increase of elderly population, number of patients also may proceed to increase.Therefore, to dementia
Preventing and treating is a problem that can not be ignored.World's each side research is a lot of, but so far still without effective remedy measures.
Chinese medicine contains multiple chemical composition due to it, can be this many in treatment dementia for multiple target spots of disease
Factor, the Complex Diseases aspect of many pathology target spot have the advantage of uniqueness.Substantial amounts of clinic and experimental data show, Chinese medicine exists
Dementia process, protection nerve cell, the suppression aspect research such as response to oxidative stress and anti-excitatory toxicity is delayed to achieve one
Fixed progress.Many research shows potentiality and the superiority of Chinese medicine dementia.If can effectively be controlled by traditional Chinese medicine merely
System dementia symptom in early days, will can avoid the toxic and side effect of Western medicine, thus be long-term treatment dementia, and effectively control dementia is entered
Journey lays the foundation, and this is perhaps the developing direction of Chinese traditional treatment dementia.
Content of the invention
For existing issue, the technical problem to be solved is to provide a kind of Chinese medicine composition improving dementia
And its preparation method and application.
In order to achieve the above object, the technology used in the present invention means are:
A kind of Chinese medicine composition improving dementia, including following components: anemarrhena asphodefoides extract, ginkgo biloba p.e, turmeric
Extract, soybean lecithin, gadol extract, milkwort extract, Fructus Alpinae Oxyphyllae extract, green-tea extract, grape pip extract
Thing, phosphatidyl serine, y-aminobutyric acid, krill oil-bound distemper and Punica granatum L. polyphenol.
The described Chinese medicine composition improving dementia, it is characterised in that the weight portion of each component is: anemarrhena asphodefoides extract
240～360 parts, ginkgo biloba p.e 240～360 parts, Turmeric P.E 160～240 parts, soybean lecithin 240～360 parts,
Gadol extract 80～120 parts, milkwort extract 240～360 parts, Fructus Alpinae Oxyphyllae extract 240～360 parts, green-tea extract
240～360 parts, grape seed extract 160～240 parts, phosphatidyl serine 160～240 parts, y-aminobutyric acid 160～240
Part, krill oil-bound distemper 160～240 parts and Punica granatum L. polyphenol 80～120 parts.
Preferably, the described Chinese medicine composition improving dementia, the weight portion of each component is: anemarrhena asphodefoides extract 270～
330 parts, ginkgo biloba p.e 270～330 parts, Turmeric P.E 180～220 parts, soybean lecithin 270～330 parts, rhodiola root
Extract 90～110 parts, milkwort extract 270～330 parts, Fructus Alpinae Oxyphyllae extract 270～330 parts, green-tea extract 270～
330 parts, grape seed extract 180～220 parts, phosphatidyl serine 180～220 parts, y-aminobutyric acid 180～220 parts, the South Pole
Krill oil-bound distemper 180～220 parts and Punica granatum L. polyphenol 90～110 parts.
It is furthermore preferred that the described Chinese medicine composition improving dementia, the weight portion of each component is: anemarrhena asphodefoides extract 300
Part, ginkgo biloba p.e 300 parts, Turmeric P.E 200 parts, soybean lecithin 300 parts, gadol extract 100 parts, polygala root carry
Take thing 300 parts, Fructus Alpinae Oxyphyllae extract 300 parts, green-tea extract 300 parts, grape seed extract 200 parts, phosphatidyl serine 200
Part, y-aminobutyric acid 200 parts, krill oil-bound distemper 200 parts and Punica granatum L. polyphenol 100 parts.
The described Chinese medicine composition improving dementia, it is characterised in that the preparation method of each component is as follows:
Anemarrhena asphodefoides extract: be dried the wind-weed, pulverize, is extracted 2-3 time by the alcohol reflux that mass percent is 70-80%,
Each 1.5-2h, each solid-liquid ratio 1-2:6-10, merge extract, filters, by filtrate spraying drying powder-forming；
Ginkgo biloba p.e: be dried ginkgo leaf, pulverize, is that 60-70% alcohol reflux extracts 2-3 with mass percent
Secondary, each 1-2h, each solid-liquid ratio 1-2:4-8, merge extract, filtration under diminished pressure, merging filtrate, filtrate is spray dried to
Powder；
Turmeric P.E: make powder after dry for turmeric stem, is 90-98% ethanolic extraction 1-2h with mass percent,
Extract is concentrated, crystallizes, be drying to obtain；
Soybean lecithin: the water adding mass percent to be 2-3% in the crude oil of soybean, is heated to 60-80 under stirring
DEG C, make phosphatide hydration jellied phosphatide slurry precipitation, centrifugation, vacuum dehydration and get final product；
Gadol extract: be dried rhodiola root, pulverize, is that 65-75% alcohol reflux extracts 2-3 with mass percent
Secondary, each 0.3-0.8h, each solid-liquid ratio 1-2:5-9, merge extract, filter, merging filtrate, filtrate is spray dried to
Powder；
Milkwort extract: be dried polygala root, pulverize, is 90-98% alcohol reflux extraction 2-3 time with mass percent, often
Secondary 1-2h, each solid-liquid ratio 1-2:5-9, merge extract, concentrates, and places under the conditions of 0-10 DEG C, and precipitation filters, discards filtrate,
By filter residue and drying and get final product；
Fructus Alpinae Oxyphyllae extract: be dried fructus alpiniae oxyphyllae, pulverize, is that 65-75% alcohol reflux extracts 2-3 with mass percent
Secondary, each 0.8-1.5h, each solid-liquid ratio 1-2:4-8, merge extract, less than 60 DEG C filtration under diminished pressure, concentrate, concentrate is cold
Freeze and be dried to powder and get final product；
Green-tea extract: be dried green tea, pulverize, is 75-85% alcohol reflux extraction 2-3 time with mass percent, often
Secondary 1-2h, each solid-liquid ratio 1-2:8-10, merge extract, filters, concentrates, is drying to obtain concentrate；
Grape seed extract: be dried grape pip, pulverize, is that 75-85% alcohol reflux extracts 2 times with mass percent,
Solid-liquid ratio is 1-2:9-10 for the first time, extracts 1.25-1.75h, and solid-liquid ratio is 1-2:7-8 for the second time, extracts 0.75-1.25h, closes
And extract twice, filter, by filtrate spraying drying powder-forming；
Krill oil-bound distemper: krill is cleaned, crushes, extract with the alcohol reflux that mass percent is 80-85%, will carry
Take liquid to concentrate, concentrate is drying to obtain；
Punica granatum L. polyphenol: after granatum pulverizing will be dried, be 65-75% ethanol heating and refluxing extraction 2.5-with mass percent
3.5h, extracts 2-3 time, merges extract, 40 DEG C of filtration under diminished pressure, merging filtrate, concentrates, concentrate freeze-drying is become powder.
The Chinese medicine composition improving dementia of the present invention, is prepared as used by clinic according to Chinese medicine conventional pharmaceutical method
Any pharmaceutical preparation.
The method that the Chinese medicine composition improving dementia of the present invention makes capsule, comprises the following steps:
Anemarrhena asphodefoides extract, ginkgo biloba p.e, Turmeric P.E, soybean lecithin, gadol extract, polygala root are extracted
Thing, Fructus Alpinae Oxyphyllae extract, green-tea extract, grape seed extract, phosphatidyl serine, y-aminobutyric acid, krill oil-bound distemper
And after Punica granatum L. polyphenol mixes, add or be added without silica or magnesium stearate, filling capsule, to obtain final product.
The method that the Chinese medicine composition improving dementia of the present invention makes pulvis, comprises the following steps:
Anemarrhena asphodefoides extract, ginkgo biloba p.e, Turmeric P.E, soybean lecithin, gadol extract, polygala root are extracted
Thing, Fructus Alpinae Oxyphyllae extract, green-tea extract, grape seed extract, phosphatidyl serine, y-aminobutyric acid, krill oil-bound distemper
And after Punica granatum L. polyphenol mixes, add or be added without silica or magnesium stearate, with pulvis pack, to obtain final product.
The method that the Chinese medicine composition improving dementia of the present invention makes tablet, comprises the following steps:
Anemarrhena asphodefoides extract, ginkgo biloba p.e, Turmeric P.E, soybean lecithin, gadol extract, polygala root are extracted
Thing, Fructus Alpinae Oxyphyllae extract, green-tea extract, grape seed extract, phosphatidyl serine, y-aminobutyric acid, krill oil-bound distemper
And after Punica granatum L. polyphenol mixes, add microcrystalline cellulose, sodium carboxymethyl starch, and with PVP k30 granulation, be subsequently adding profit
Lubrication prescription, compressing tablet, to obtain final product.
The method that the Chinese medicine composition improving dementia of the present invention makes granule, comprises the following steps:
Anemarrhena asphodefoides extract, ginkgo biloba p.e, Turmeric P.E, soybean lecithin, gadol extract, polygala root are extracted
Thing, Fructus Alpinae Oxyphyllae extract, green-tea extract, grape seed extract, phosphatidyl serine, y-aminobutyric acid, krill oil-bound distemper
And after Punica granatum L. polyphenol mixes, add microcrystalline cellulose, sodium carboxymethyl starch, and with PVP k30 granulation, pack, to obtain final product.
The Chinese medicine composition improving dementia of the present invention improves in medicine and the health products of dementia in preparation
Application.
The Chinese medicine composition of the present invention can obviously reduce β-AP plaque area in brain, and can be obviously improved injection zone week
Enclosing and the form of regional nerve cell and quantity farther out, the neurotoxicity causing β-AP has protective effect.Meanwhile, this reality
Test the effect by studying this Chinese medicine composition dementia animal model and mechanism of action, for research and development treatment dementia further
Chinese medicine provides objective basis.
Detailed description of the invention
Further describe the present invention below in conjunction with specific embodiment, advantages of the present invention and feature will be with describe and
Apparent.But embodiment is only exemplary, any restriction is not constituted to the scope of the present invention.Those skilled in the art should
It should be appreciated that, the details of technical solution of the present invention and form can be repaiied lower without departing from the spirit and scope of the present invention
Change or replace, but these modifications and replacement each fall within protection scope of the present invention.
The preparation of each component in embodiment 1 Chinese medicine composition
Anemarrhena asphodefoides extract: be dried the wind-weed, pulverize, extracts 3 times with alcohol reflux that mass percent is 75%, every time
2h, each solid-liquid ratio 1:8, merge extract, filters, by filtrate spraying drying powder-forming；
Ginkgo biloba p.e: be dried ginkgo leaf, pulverize, is 65% alcohol reflux extraction 3 times with mass percent, every time
1.5h, each solid-liquid ratio 1:6, merge extract, and filtration under diminished pressure, merging filtrate, by filtrate spraying drying powder-forming；
Turmeric P.E: make powder after dry for turmeric stem, is 95% ethanolic extraction 1h with mass percent, will extract
Liquid concentrates, crystallization, is drying to obtain；
Soybean lecithin: the water adding mass percent to be 2-3% in the crude oil of soybean, is heated to 75 DEG C under stirring,
Make phosphatide hydration jellied phosphatide slurry precipitation, centrifugation, vacuum dehydration and get final product；
Gadol extract: be dried rhodiola root, pulverize, is 70% alcohol reflux extraction 3 times with mass percent, every time
0.5h, each solid-liquid ratio 1:7, merge extract, filters, and merging filtrate, by filtrate spraying drying powder-forming；
Milkwort extract: be dried polygala root, pulverize, is 95% alcohol reflux extraction 3 times with mass percent, every time
1.5h, each solid-liquid ratio 1:7, merge extract, concentrates, and places under the conditions of 0-5 DEG C, and precipitation filters, discards filtrate, by filter residue
It is drying to obtain；
Fructus Alpinae Oxyphyllae extract: be dried fructus alpiniae oxyphyllae, pulverize, is 70% alcohol reflux extraction 3 times with mass percent, every time
1h, each solid-liquid ratio 1:6, merge extract, less than 60 DEG C filtration under diminished pressure, concentrate, concentrate freeze-drying is become powder and get final product；
Green-tea extract: be dried green tea, pulverize, is 80% alcohol reflux extraction 3 times with mass percent, every time
1.5h, each solid-liquid ratio 1:9, merge extract, filters, concentrates, is drying to obtain concentrate；
Grape seed extract: be dried grape pip, pulverize, is 80% alcohol reflux extraction 2 times with mass percent, first
Secondary solid-liquid ratio is 1:10, extracts 1.5h, and solid-liquid ratio is 1:8 for the second time, extracts 1h, merges extract twice, filters, and sprays filtrate
Mist is dried to powder；
Krill oil-bound distemper: clean krill, crush, extract with the alcohol reflux that mass percent is 85%, will extract
Liquid concentrates, is drying to obtain concentrate；
Punica granatum L. polyphenol: after granatum pulverizing will be dried, be 70% ethanol heating and refluxing extraction 3h with mass percent, extract
2-3 time, merge extract, 40 DEG C of filtration under diminished pressure, merging filtrate, concentrate, concentrate freeze-drying is become powder.
GABA and phosphatidyl serine are and are commercially available.
Prepared by the capsule of embodiment 2 Chinese medicine composition
Weigh according to embodiment 1 preparation: anemarrhena asphodefoides extract 300g, ginkgo biloba p.e 300g, Turmeric P.E 200g,
Soybean lecithin 300g, gadol extract 100g, milkwort extract 300g, Fructus Alpinae Oxyphyllae extract 300g, green-tea extract
300g, grape seed extract 200g, phosphatidyl serine 200g, y-aminobutyric acid 200g, krill oil-bound distemper 200g and pomegranate
Polyphenol 100g.
Above-mentioned Chinese medicine composition is prepared as the method for capsule:
Anemarrhena asphodefoides extract, ginkgo biloba p.e, Turmeric P.E, soybean lecithin, gadol extract, polygala root are extracted
Thing, Fructus Alpinae Oxyphyllae extract, green-tea extract, grape seed extract, phosphatidyl serine, y-aminobutyric acid, krill oil-bound distemper
And after Punica granatum L. polyphenol mixes, add silica 4g, filling capsule, to obtain final product, wherein, every seed lac capsule contains above-mentioned Chinese traditional medicine composition
Thing 0.5g.
Prepared by the pulvis of embodiment 3 Chinese medicine composition
Weigh according to embodiment 1 preparation: anemarrhena asphodefoides extract 260g, ginkgo biloba p.e 300g, Turmeric P.E 180g,
Soybean lecithin 320g, gadol extract 90g, milkwort extract 340g, Fructus Alpinae Oxyphyllae extract 280g, green-tea extract
320g, grape seed extract 240g, phosphatidyl serine 180g, y-aminobutyric acid 200g, krill oil-bound distemper 210g and pomegranate
Polyphenol 110g.
Above-mentioned Chinese medicine composition is prepared as the method for pulvis:
Anemarrhena asphodefoides extract, ginkgo biloba p.e, Turmeric P.E, soybean lecithin, gadol extract, polygala root are extracted
Thing, Fructus Alpinae Oxyphyllae extract, green-tea extract, grape seed extract, phosphatidyl serine, y-aminobutyric acid, krill oil-bound distemper
And after Punica granatum L. polyphenol mixes, add magnesium stearate 10g, and with pulvis pack, to obtain final product, wherein, every bag contains above-mentioned Chinese traditional medicine composition
Thing 1.5g.
Prepared by the tablet of embodiment 4 Chinese medicine composition
Weigh according to embodiment 1 preparation: anemarrhena asphodefoides extract 320g, ginkgo biloba p.e 340g, Turmeric P.E 220g,
Soybean lecithin 260g, gadol extract 120g, milkwort extract 250g, Fructus Alpinae Oxyphyllae extract 320g, green-tea extract
270g, grape seed extract 180g, phosphatidyl serine 230g, y-aminobutyric acid 220g, krill oil-bound distemper 180g and pomegranate
Polyphenol 90g.
Above-mentioned Chinese medicine composition is prepared as the method for tablet:
Anemarrhena asphodefoides extract, ginkgo biloba p.e, Turmeric P.E, soybean lecithin, gadol extract, polygala root are extracted
Thing, Fructus Alpinae Oxyphyllae extract, green-tea extract, grape seed extract, phosphatidyl serine, y-aminobutyric acid, krill oil-bound distemper
And after Punica granatum L. polyphenol mixes, add microcrystalline cellulose 220g and sodium carboxymethyl starch 50g, and with addition PVP k30
30g, granulation, add lubricant 10g, compressing tablet, to obtain final product, wherein, every contains above-mentioned Chinese medicine composition 0.5g.
Prepared by the granule of embodiment 5 Chinese medicine composition
Weigh according to embodiment 1 preparation: anemarrhena asphodefoides extract 300g, ginkgo biloba p.e 270g, Turmeric P.E 240g,
Soybean lecithin 280g, gadol extract 80g, milkwort extract 280g, Fructus Alpinae Oxyphyllae extract 345g, green-tea extract
350g, grape seed extract 230g, phosphatidyl serine 160g, y-aminobutyric acid 170g, krill oil-bound distemper 230g and pomegranate
Polyphenol 120g.
Above-mentioned Chinese medicine composition is prepared as the method for granule:
Anemarrhena asphodefoides extract, ginkgo biloba p.e, Turmeric P.E, soybean lecithin, gadol extract, polygala root are extracted
Thing, Fructus Alpinae Oxyphyllae extract, green-tea extract, grape seed extract, phosphatidyl serine, y-aminobutyric acid, krill oil-bound distemper
And after Punica granatum L. polyphenol mixes, add microcrystalline cellulose 220g and sodium carboxymethyl starch 50g, and with addition PVP k30
30g, granulation, pack, to obtain final product.Wherein, every bag of granule contains above-mentioned Chinese medicine composition 1.5g.
Embodiment 6 is in the Chinese medicine composition application clinically of the present invention
1. experiment material
1.1 experimental drug
Tested material used is the capsule that embodiment 1 prepares.
β-AP25-35；Iibotenicacid (IBO), is configured to 2g/L with SPSS；It is more than Sigma company to produce
Product.
1.2 animal used as test
Select the adult male SD rats (220～250g) 60 of Military Medical Science Institute's Experimental Animal Center breeding, real
Test animal and use credit number SYXK (capital) 2012-0020.
1.3 testing equipment
CM-1900 freezing-microtome, Germany's LEICA Products；BH-2 type OLYMPUS carries camera microscope, Japan
OLYMPUS Products；KS400 type computerized image analysis sgstem, Germany's KAISER Products.
2. test method
2.1 SD rat feedings
Operation consent is raised 1 week, free diet, room temperature 20-22 DEG C, illumination every day 12h.
2.2 SD rat packets
Animal is randomly divided into 5 groups (often organizing 12): control group, model group, model+tested material low dose group, model+be subject to
Dosage group, model+tested material high dose group in examination thing, the dosage of the every day of basic, normal, high three dosage groups is respectively human body every day
2.5 times of RD, 5 times, 15 times, human body RD every day is 50mg/ day/kg body weight, namely 125mg/ day/kg body
Weight, 250mg/ day/kg body weight, 750mg/ day/kg body weight.
2.3 SD Model of Dementia in Rats
Positioning SD rats underwent brain, right unilateral injects β-AP25-35.Every model group and tested material group SD rat note
Emitter shot β-AP25-35With the mixed liquor 1 μ L of IBO, control group is with side injection 1 μ L SPSS.
Within postoperative 4 days, rising, gavage volume is 0.5ml/100g rat, tested material group rat gavage every day tested material mass concentration
Being the CMC-Na suspension of 5%, control group and the CMC-Na that model group rats gavage every day equal-volume mass concentration is 5% are molten
Matchmaker.Continuous gavage 30d.
After last is administered, sacrificed by decapitation animal, take right hemisphere, freezing immediately, make coronal section with freezing-microtome,
Piece thickness is 6 μm.Dyeing, uses neutral gum sealing.
2.4 photomicrographies and graphical analysis
Inject β-AP at 40 times of Microscopic observations25-35The deposition patch being formed is yellow spotting, edge clear.5 groups of sample choosings
Selecting same area, 2 visuals field are selected in every section.During photography, search out desired area under the microscope, bring into focus, with 100 times
Mirror shoots.Often group randomly selects 1 section, and each section randomly selects 1 patch, carries out gray scale with computerized image analysis sgstem
Measure, with 100-152 for standard gray angle value scope.Each patch measures speck area and the ratio of the whole gross area of cutting into slices, than
Value (%)=speck area/gross area × 100%.Ratio is bigger, then show that amount of speckle or area are bigger, finally checked by t
Carry out statistical disposition.
The mensuration of cholinacetyltranslase (ChAT) activity in 2.5 brain tissues
The activity of ChAT represents with the acetylcholine (Achnmol/h/mg prot) being formed.
M receptor density measurement in 2.6 brains
Measuring brain total m receptor density by 3H-QNB single-point method, Lowry method measures brain protein density.Rd is with MR value
(fmol/mg prot) represents.
3. experimental result
3.1 plaque deposition and the morphologic change of nerve cell
Found with graphical analysis by photomicrography, SD rat intracerebral injection β-AP25-35After+IBO 30d, staining brain sections
Display, all visible yellow precipitates in the most section of model group.From form, focusing mostly on greatly in one piece of patch, have cuts
Piece is dispersed into several little patch or spot.The section of tested material group also shows similar yellow deposition spot, individual slices
Also show syringe needle travel track, but the depositional area of section is little compared with model group.Around β-AP patch or near, it is seen that base
End nucleus neuron generation denaturation and quantity reduce, and the phenomena of mortality such as diabrosis, cavity, pyknosis and karyon minimizing occur such as cell, with
The denaturation of patch peripheral nerve unit is the most obvious.
The impact on β-AP deposition patch gray value and nerve cell in SD dementia rats brain for 3.2 tested materials
Obtain the gross area of each section yellow deposition patch with image analyzer, obtain average and the standard of each group of area
Difference, the results are shown in Table 1.It can be seen that the animal brain piece of intracerebral injection physiological saline deposits without any yellow.And model group animal
Brain piece deposition plaque area is then bigger, model+tested material treated animal brain piece β-AP deposit plaque area and quantity all substantially than
Model group is few, and statistics shows that average is all that model group is more than model+tested material group, P ＜ 0.05.It is moreover found that model+tested
In thing treated animal brain β-AP deposition patch around and farther out regional nerve cell quantity substantially many than model group, cellular morphology recover
Preferably, dyeing display karyon significantly increases.This shows, the deposition to β-AP for the tested material may have elimination effect and contribute to protection
Nerve cell.
The impact (x ± s) on β-AP deposition plaque area in dementia rats brain for table 1 tested material
* compare with model group, P ＜ 0.05
The impact on cholinacetyltranslase ChAT activity in SD dementia rats brain tissue for 3.3 tested materials
As seen from Table 2, in model group rats brain, ChAT activity is significantly lower than control group, and this shows, ChAT is lived by β-AP
Property has inhibitory action.And after SD rat model gavage tested material 30d, ChAT activity is significantly raised, this shows, tested material to β-
The ChAT activity reduction that AP causes is improved effect.
The impact on m receptor density total in SD dementia rats brain for 3.4 tested materials
Table 2 shows shot β-AP in brain, and in model group rats brain, total m receptor density is consistently lower than Normal group,
Illustrate that β-AP can reduce brain m receptor density, and after SD rat model gavage tested material 30d, m receptor density be significantly raised again,
This shows, tested material can be obviously improved the m receptor density reduction that β-AP causes.
The impact (x ± s) on dementia rats brain ChAT activity and brain total m receptor density for table 2 tested material
* compare with control group, P < 0.01；* compares with model group, P < 0.01
More than test by the Chinese medicine composition studying the present invention to the therapeutic action of dementia animal model and effect machine
System, the new drug for research and development treatment dementia further provides objective basis.
Claims (10)
1. the Chinese medicine composition improving dementia, it is characterised in that include following components: anemarrhena asphodefoides extract, ginkgo leaf carry
Take thing, Turmeric P.E, soybean lecithin, gadol extract, milkwort extract, Fructus Alpinae Oxyphyllae extract, green-tea extract, Portugal
Grape seed extract, phosphatidyl serine, y-aminobutyric acid, krill oil-bound distemper and Punica granatum L. polyphenol.
2. improve the Chinese medicine composition of dementia as claimed in claim 1, it is characterised in that the weight portion of each component is: know
Female extract 240～360 parts, ginkgo biloba p.e 240～360 parts, Turmeric P.E 160～240 parts, soybean lecithin 240
～360 parts, gadol extract 80～120 parts, milkwort extract 240～360 parts, Fructus Alpinae Oxyphyllae extract 240～360 parts, green
Tea extraction 240～360 parts, grape seed extract 160～240 parts, phosphatidyl serine 160～240 parts, y-aminobutyric acid
160～240 parts, krill oil-bound distemper 160～240 parts and Punica granatum L. polyphenol 80～120 parts；
Preferably, the weight portion of each component is: anemarrhena asphodefoides extract 270～330 parts, ginkgo biloba p.e 270～330 parts, turmeric
Extract 180～220 parts, soybean lecithin 270～330 parts, gadol extract 90～110 parts, milkwort extract 270～
330 parts, Fructus Alpinae Oxyphyllae extract 270～330 parts, green-tea extract 270～330 parts, grape seed extract 180～220 parts, phosphide
Acyl serine 180～220 parts, y-aminobutyric acid 180～220 parts, krill oil-bound distemper 180～220 parts and Punica granatum L. polyphenol 90～
110 parts.
3. improve the Chinese medicine composition of dementia as claimed in claim 1, it is characterised in that the weight portion of each component is: know
Female extract 300 parts, ginkgo biloba p.e 300 parts, Turmeric P.E 200 parts, soybean lecithin 300 parts, gadol extract
100 parts, milkwort extract 300 parts, Fructus Alpinae Oxyphyllae extract 300 parts, green-tea extract 300 parts, grape seed extract 200 parts, phosphorus
Ester acyl serine 200 parts, y-aminobutyric acid 200 parts, krill oil-bound distemper 200 parts and Punica granatum L. polyphenol 100 parts.
4. improve the Chinese medicine composition of dementia as claimed in claim 1, it is characterised in that the preparation method of each component is such as
Under:
Anemarrhena asphodefoides extract: be dried the wind-weed, pulverize, extracts 2-3 time with alcohol reflux that mass percent is 70-80%, every time
1.5-2h, each solid-liquid ratio 1-2:6-10, merge extract, filters, by filtrate spraying drying powder-forming；
Ginkgo biloba p.e: be dried ginkgo leaf, pulverize, is 60-70% alcohol reflux extraction 2-3 time with mass percent, often
Secondary 1-2h, each solid-liquid ratio 1-2:4-8, merge extract, and filtration under diminished pressure, merging filtrate, by filtrate spraying drying powder-forming；
Turmeric P.E: make powder after dry for turmeric stem, is 90-98% ethanolic extraction 1-2h with mass percent, will carry
Take liquid to concentrate, crystallize, be drying to obtain；
Soybean lecithin: the water adding mass percent to be 2-3% in the crude oil of soybean, is heated to 60-80 DEG C under stirring, makes
Phosphatide hydration jellied phosphatide slurry precipitation, centrifugation, vacuum dehydration and get final product；
Gadol extract: be dried rhodiola root, pulverize, is 65-75% alcohol reflux extraction 2-3 time with mass percent, often
Secondary 0.3-0.8h, each solid-liquid ratio 1-2:5-9, merge extract, filters, and merging filtrate, by filtrate spraying drying powder-forming；
Milkwort extract: be dried polygala root, pulverize, is that 90-98% alcohol reflux extracts 2-3 time with mass percent, each 1-
2h, each solid-liquid ratio 1-2:5-9, merge extract, concentrates, and places under the conditions of 0-10 DEG C, and precipitation filters, and discards filtrate, will filter
Slag is drying to obtain；
Fructus Alpinae Oxyphyllae extract: be dried fructus alpiniae oxyphyllae, pulverize, is 65-75% alcohol reflux extraction 2-3 time with mass percent, often
Secondary 0.8-1.5h, each solid-liquid ratio 1-2:4-8, merge extract, less than 60 DEG C filtration under diminished pressure, concentrate, and does freezing for concentrate
Dry one-tenth powder and get final product；
Green-tea extract: be dried green tea, pulverize, is that 75-85% alcohol reflux extracts 2-3 time with mass percent, each 1-
2h, each solid-liquid ratio 1-2:8-10, merge extract, filters, concentrates, is drying to obtain concentrate；
Grape seed extract: be dried grape pip, pulverize, is 75-85% alcohol reflux extraction 2 times with mass percent, first
Secondary solid-liquid ratio is 1-2:9-10, extracts 1.25-1.75h, and solid-liquid ratio is 1-2:7-8 for the second time, extracts 0.75-1.25h, merges two
Secondary extract, filters, by filtrate spraying drying powder-forming；
Krill oil-bound distemper: krill is cleaned, crushes, extract with the alcohol reflux that mass percent is 80-85%, by extract
Concentrate, concentrate is drying to obtain；
Punica granatum L. polyphenol: after granatum pulverizing will be dried, be 65-75% ethanol heating and refluxing extraction 2.5-with mass percent
3.5h, extracts 2-3 time, merges extract, 40 DEG C of filtration under diminished pressure, merging filtrate, concentrates, concentrate freeze-drying is become powder.
5. the Chinese medicine composition improving dementia as described in any one of claim 1-4, it is characterised in that conventional according to Chinese medicine
Pharmaceutical methods is prepared as any pharmaceutical preparation used by clinic.
6. the method Chinese medicine composition improving dementia described in any one of claim 1-4 being made capsule, its feature
It is, comprise the following steps:
By anemarrhena asphodefoides extract, ginkgo biloba p.e, Turmeric P.E, soybean lecithin, gadol extract, milkwort extract,
Fructus Alpinae Oxyphyllae extract, green-tea extract, grape seed extract, phosphatidyl serine, y-aminobutyric acid, krill oil-bound distemper and stone
After pomegranate polyphenol mixes, add or be added without silica or magnesium stearate, filling capsule, to obtain final product.
7. the method Chinese medicine composition improving dementia described in any one of claim 1-4 being made pulvis, its feature exists
In comprising the following steps:
By anemarrhena asphodefoides extract, ginkgo biloba p.e, Turmeric P.E, soybean lecithin, gadol extract, milkwort extract,
Fructus Alpinae Oxyphyllae extract, green-tea extract, grape seed extract, phosphatidyl serine, y-aminobutyric acid, krill oil-bound distemper and stone
After pomegranate polyphenol mixes, add or be added without silica or magnesium stearate, with pulvis pack, to obtain final product.
8. the method Chinese medicine composition improving dementia described in any one of claim 1-4 being made tablet, its feature exists
In comprising the following steps:
By anemarrhena asphodefoides extract, ginkgo biloba p.e, Turmeric P.E, soybean lecithin, gadol extract, milkwort extract,
Fructus Alpinae Oxyphyllae extract, green-tea extract, grape seed extract, phosphatidyl serine, y-aminobutyric acid, krill oil-bound distemper and stone
After pomegranate polyphenol mixes, add microcrystalline cellulose, sodium carboxymethyl starch, and with PVP k30 granulation, be subsequently adding lubrication
Agent, compressing tablet, to obtain final product.
9. the method Chinese medicine composition improving dementia described in any one of claim 1-4 being made granule, its feature
It is, comprise the following steps:
By anemarrhena asphodefoides extract, ginkgo biloba p.e, Turmeric P.E, soybean lecithin, gadol extract, milkwort extract,
Fructus Alpinae Oxyphyllae extract, green-tea extract, grape seed extract, phosphatidyl serine, y-aminobutyric acid, krill oil-bound distemper and stone
After pomegranate polyphenol mixes, add microcrystalline cellulose, sodium carboxymethyl starch, and with PVP k30 granulation, pack, to obtain final product.
10. the Chinese medicine composition improving dementia as described in any one of claim 1-4 improves the medicine of dementia in preparation
Or the application in health products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610649985.XA CN106139019B (en) | 2016-08-10 | 2016-08-10 | A kind of Chinese medicine composition and its preparation method and application improving dementia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610649985.XA CN106139019B (en) | 2016-08-10 | 2016-08-10 | A kind of Chinese medicine composition and its preparation method and application improving dementia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106139019A true CN106139019A (en) | 2016-11-23 |
| CN106139019B CN106139019B (en) | 2019-10-01 |
Family
ID=57328956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610649985.XA Active CN106139019B (en) | 2016-08-10 | 2016-08-10 | A kind of Chinese medicine composition and its preparation method and application improving dementia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106139019B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109331143A (en) * | 2018-10-30 | 2019-02-15 | 河西学院 | A kind of desert cistanche compound and its preparation method |
| WO2020089903A1 (en) * | 2018-11-04 | 2020-05-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nasal compositions and methods |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101168025A (en) * | 2007-10-25 | 2008-04-30 | 张占军 | Medicine composition for preventing and treating senile dementia |
| CN102028220A (en) * | 2011-01-07 | 2011-04-27 | 济南老来寿生物股份有限公司 | Functional food for improving senile dementia |
| CN103041060A (en) * | 2013-01-21 | 2013-04-17 | 李庆杰 | Drug composition conducive to improvement of memory and adjunctive treatment of senile dementia |
-
2016
- 2016-08-10 CN CN201610649985.XA patent/CN106139019B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101168025A (en) * | 2007-10-25 | 2008-04-30 | 张占军 | Medicine composition for preventing and treating senile dementia |
| CN102028220A (en) * | 2011-01-07 | 2011-04-27 | 济南老来寿生物股份有限公司 | Functional food for improving senile dementia |
| CN103041060A (en) * | 2013-01-21 | 2013-04-17 | 李庆杰 | Drug composition conducive to improvement of memory and adjunctive treatment of senile dementia |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109331143A (en) * | 2018-10-30 | 2019-02-15 | 河西学院 | A kind of desert cistanche compound and its preparation method |
| CN109331143B (en) * | 2018-10-30 | 2022-07-08 | 河西学院 | A herba cistanches Deserticolae composition and its preparation method |
| WO2020089903A1 (en) * | 2018-11-04 | 2020-05-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nasal compositions and methods |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106139019B (en) | 2019-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4943846B2 (en) | Pharmaceutical compositions for the treatment of cardiovascular and cerebrovascular diseases | |
| WO2015039619A1 (en) | Use of yangxueqingnao formulation in preparation of medicine for treating alzheimer's disease | |
| CN106139019A (en) | A kind of Chinese medicine composition improving dementia and its preparation method and application | |
| CN103919854B (en) | Application of butterflybush flower and extract thereof to preparation of medicament | |
| CN104027428B (en) | Preparation method of traditional Chinese medicine compound and application of traditional Chinese medicine compound in prevention and treatment of senile dementia | |
| CN105055785B (en) | A kind of Chinese medicine composition for treating diabetic retinopathy | |
| CN103735761B (en) | A kind of pharmaceutical composition preventing and treating Alzheimer disease and preparation method thereof | |
| CN108434166A (en) | A kind of " Xuesaitong Injection " pharmaceutical composition and preparation method thereof, preparation and application | |
| CN102861117A (en) | Composition containing Chinese medicine active ingredients and application thereof | |
| CN102293847B (en) | Chinese medicinal composition for treating constipation, acne and hyperlipidemia, and preparation method | |
| CN105168435A (en) | Lucid ganoderma composition preparation, and preparation method and application thereof | |
| CN109260397A (en) | A kind of Chinese medicine composition for treating Vascular retinopathy | |
| CN106163515A (en) | Anticancer and agents for relieving side effects | |
| CN104147380A (en) | Pharmaceutical composition for relieving asthenopia, preparation method and applications thereof | |
| CN105878470A (en) | Qingkailing pharmaceutical composition | |
| CN105878374A (en) | Composition containing salvia miltiorrhiza fat soluble ingredients and coenzyme Q10, preparation method of composition and drug containing composition | |
| CN106727928A (en) | Prunella vulgaris extract and preparation method and application | |
| CN102920845B (en) | Traditional Chinese medicine composition for treating fundus macular degeneration and preparation method of traditional Chinese medicine composition | |
| CN1730018B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and preparing process and application thereof | |
| DE60222993T2 (en) | Composition of traditional Chinese medicines for the prophylaxis and treatment of cerebrovascular diseases | |
| CN105816549B (en) | A kind of drug and preparation method thereof for preventing and treating atherosclerotic plaque | |
| CN108042552A (en) | A kind of pharmaceutical composition containing Aescinate B | |
| CN109044997A (en) | The new application of cinnaldehydrum | |
| CN106924655A (en) | A kind of preparation method of the Chinese medicine composition for treating AMD | |
| CN106822205A (en) | Ring conopsea extraction is preparing the application for the treatment of kidney fibrosis medicine and composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |